OV56Homo sapiens (Human)Cancer cell line

Also known as: OV-56

🤖 AI SummaryBased on 7 publications

Quick Overview

OV56 is a human cell line derived from ovarian cancer, used for cancer research.

Detailed Summary

OV56 is a human cell line derived from ovarian cancer, commonly used in cancer research to study tumor biology and drug responses. It is part of the Cancer Cell Line Encyclopedia (CCLE) and has been analyzed for genomic profiles, drug sensitivity, and molecular characteristics. Research indicates that OV56 exhibits specific genomic features and may be used to investigate therapeutic targets and cancer progression mechanisms. However, detailed information about its tissue origin and disease characteristics is limited.
Generated on 6/19/2025

Basic Information

Database IDCVCL_2673
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age46
Age CategoryAdult
SexFemale

Disease Information

DiseaseOvarian serous adenocarcinoma
LineageOvary/Fallopian Tube
SubtypeSerous Ovarian Cancer
OncoTree CodeSOC

DepMap Information

Source TypeECACC
Source IDACH-000091_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Lys101_Thr102fs (c.303_304delAA)Heterozygous-Unknown, PubMed=28273451, PubMed=25230021
MutationSimplePTENp.Arg130Gly (c.388C>G)Homozygous-Unknown, Unknown, PubMed=28273451
MutationSimpleKRASp.Gly12Cys (c.34G>T)Unspecified-PubMed=21173094
MutationSimpleARID1Ap.Asp2178Glyfs*47 (c.6527_6528insG)Heterozygous-Unknown, PubMed=25230021

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
8,9
D16S539
10,13
D18S51
14
D19S433
13,15
D21S11
28
D2S1338
20,24
D3S1358
16,17
D5S818
11,12
D7S820
10
D8S1179
8,14
FGA
21
Penta D
13,15
Penta E
12,20
TH01
6,9
TPOX
9,11
vWA
15,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

Barker P.J., Wright K.A., Twentyman P.R., Smith S.K.

J. Natl. Cancer Inst. 87:506-516(1995).